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A B S T R A C T
Background: Toxoplasmosis constitutes a large global burden that is further exacerbated by the shortcomings of
available therapeutic options, thus underscoring the urgent need for better anti-Toxoplasma gondii therapy or
strategies. Recently, we showed that the anti-parasitic action of inorganic nanoparticles (NPs) could, in part, be
due to changes in redox status as well as in the parasite mitochondrial membrane potential.
Methods: In the present study, we explored the in vitro mode of action of the anti-T. gondii eﬀect of NPs by
evaluating the contributions of host cellular processes, including the tryptophan pathway and hypoxia-inducing
factor activity. NPs, at concentrations ranging from 0.01 to 200 µg/ml were screened for anti-parasitic activity.
Sulfadiazine and/or pyrimethamine served as positive controls.
Results: We found that interplay among multiple host cellular processes, including HIF-1α activity, indoleamine
2,3-dioxygenase activity, and to a larger extent the tryptophan pathway, contribute to the anti-parasitic action of
NPs.
Conclusion: To our knowledge, this is the ﬁrst study to demonstrate an eﬀect of NPs on the tryptophan and/or
kynurenine pathway.
General signiﬁcance: Our ﬁndings deepen our understanding of the mechanism of action of NPs and suggest that
modulation of the host nutrient pool may represent a viable approach to the development of new and eﬀective
anti-parasitic agents.
1. Introduction
Toxoplasma gondii is the causative agent of toxoplasmosis, a para-
sitic disease that constitutes a serious public health challenge world-
wide [1,2]. T. gondii has low speciﬁcity and infects a range of hosts;
accordingly, the parasitic disease it causes is common and widespread,
aﬀecting more than 60% of the world population [3,4]. The T. gondii
infection is usually asymptomatic in healthy individuals, but can be
fatal in pregnant or immunocompromised individuals [5]. In healthy
individuals, the T. gondii infection is controlled by the immune system
and appropriate medication, but cysts remain in all infected tissues
including the brain and these may serve as a source for exacerbations
particularly in immunocompromised individuals. Available treatment
options for toxoplasmosis patients are limited, but include the use of
anti-malarial drugs or antibiotics, which often cause serious side eﬀects
including bone marrow suppression and rashes [5]. Consequently,
toxoplasmosis remains a large global burden that is further enhanced by
the shortcomings of current therapeutic options. These factors drive the
search for better anti-T. gondii drugs and/or new approaches to the
treatment of toxoplasmosis.
Recently, we showed that inorganic nanoparticles (NPs) including
Au, Ag, and Pt nanoparticles caused T. gondii death partially via
changes in redox status and parasite mitochondria membrane potential
[6]. However, since nanomedicine is still in its infancy, the modes of
action of many NPs that appear to be bioactive remain poorly under-
stood [7]. To further our understanding of the mode of action of NPs as
it relates to their anti-T. gondii activity [6], we examined the host
contribution to the anti-parasitic action of nanoparticles. In our earlier
report [6], we determined that oxidative stress plays a part in the anti-
parasitic action of NPs, but evidence [6] suggests that modulation of
host cellular processes also contributes to the NP-induced anti-parasitic
eﬀect. Interestingly, NPs have the potential to aﬀect several cellular
signaling processes, including the activity of hypoxia-inducible factor 1
(HIF-1) [8–10]. HIF-1 is a heterodimer consisting of α and β subunits. It
plays a remarkable role in T. gondii survival in the host by regulating
pro-parasite genes including glycolytic metabolic genes, transferrin
receptor, and vascular endothelial growth factors [11–13]. Moreover,
increased levels of HIF-1 protein and activity are not restricted to
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hypoxic stress as many pathogens including T. gondii activate HIF-1
[14], and loss of the HIF-1α subunit has been shown to cause a sig-
niﬁcant reduction in parasite growth at physiological oxygen levels
[15].
Furthermore, given that T. gondii is an obligate intracellular para-
site, it must satisfy its nutritional needs by scavenging essential nu-
trients such as tryptophan from its host [16]. Therefore, this may re-
present an opportunity for the host to naturally restrict parasite growth
by modulating nutrient pools. For example, in human cells, the in-
ducible enzyme indoleamine 2,3-dioxygenase (IDO) reduces local
tryptophan levels and is therefore able to mediate broad spectrum ef-
fector functions including restricting the growth of various clinically
relevant pathogens [17]. IDO belongs to the family of heme enzymes
that catalyze the oxidative degradation of tryptophan, which the
parasite cannot synthesize de novo [18]. Previous studies have shown
that the parasite grows unhindered if IDO function is impaired [17] and
the suppressive eﬀect of IDO on parasite growth can be reversed by the
addition of excess tryptophan to the growth medium [18]. Taken to-
gether, these studies suggest that tryptophan starvation may represent a
critical anti-parasitic pathway. Moreover, hypoxia with a concomitant
increase in HIF-1α level has been linked to reduced IDO expression [17]
leading to a sparing eﬀect on the local tryptophan pool that conse-
quently may support parasite growth. Therefore, we asked whether NP
treatment aﬀects host cellular processes in a way that helps to restrict
parasite growth and sought to determine likely host cellular processes
involved in mediating the anti-parasitic action of NPs. The present
study provides evidence that modulation of HIF-1α levels, IDO activity,
and the tryptophan pathway in host cells partially mediates the anti-
parasitic action of NPs.
2. Materials and methods
2.1. Materials
Nanoparticles (NPs), including gold (AuNP, 5 nm), silver (AgNP,
10 nm), and platinum (PtNP, 3 nm), were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The NPs were used as supplied after
evaluation to conﬁrm the supplier's speciﬁcations. The NPs were re-
constituted in fresh culture medium prior to each use. L-tryptophan, L-
kynurenine, cobalt (II) chloride (CoCl2), 4-(dimethylamino) benzalde-
hyde, 1-Methyl-D-tryptophan (DMT), and 3-(5′-Hydroxymethyl-2′-
furyl)-1-benzyl indazole (YC-1) were obtained from Sigma-Aldrich.
Dexamethasone sodium phosphate and 6-hydroxy-2,5,7,8-tetra-
methylchroman-2-carboxylic acid (trolox) were obtained from Wako
Pure Chemicals (Osaka, Japan); (± )3,4-dihydro-3-hydroxy-2,2-di-
methyl-4-[(phenylmethyl)amino]-2H-naphtho[2,3-b]pyran-5,10-dione
(a naphthoquinone derivative – NQ) was obtained from Cayman
Chemicals (Ann Arbor, MI, USA). All reagents were of analytical grade
and used as supplied unless otherwise stated.
2.2. Parasite strain
A luciferase-expressing parasite strain, T. gondii RH-2F [19], was
used for this study. The parasite was maintained by repeated passages
in monolayers of human foreskin ﬁbroblast cells (HFF; ATCC®, Mana-
ssas, VA, USA) cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM;
Nissui, Tokyo, Japan) and supplemented with GlutaMAX™-I (Gibco,
Invitrogen, Waltham, MA, USA), 10% (v/v) fetal calf serum (FCS;
Gibco, Invitrogen, Waltham, MA, USA), and penicillin and streptomycin
(10,000 U/ml; Leicestershire, UK). The number of T. gondii tachyzoites
was determined through a luminescence-based assay of β-galactosidase
(β-gal) activity expressed by the parasite strain RH-2F. To obtain a
puriﬁed parasite suspension for the assays, infected cells were passed
through a 27-gauge needle to lyse them and the lysates were ﬁltered to
remove cell debris. The parasite suspension free of host cell debris was
then washed with fresh culture medium. Parasite density was measured
with a hemocytometer and adjusted for in vitro experimental infection
analysis.
2.2.1. The anti-T. gondii potential of NPs in vitro
NP doses were selected on the basis of our previous ﬁndings [6], and
in vitro growth inhibition assays were performed as previously de-
scribed [6]. Brieﬂy, puriﬁed parasite suspension plus the NPs (recon-
stituted in culture medium prior to use) was added to growing HFF
monolayers and incubated for 48 h. The untreated but infected cells
served as controls, whereas the culture medium only well was used to
correct for the background signal. Sulfadiazine (Sigma, St Louis, MO,
USA) and/or pyrimethamine (Wako Pure Chemical, Osaka, Japan) were
included as positive controls. After the 48-h incubation at 37 °C in a 5%
CO2 atmosphere, the viability of the RH-2F parasite strain was de-
termined by assaying for galactosidase activity by using a Beta-Glo
luminescent assay kit (Promega, Madison, WI, USA). The assay was
performed in triplicate and repeated three times independently. All
experiments were performed in 96-well solid white plates (Nunc; Fisher
Scientiﬁc, Pittsburgh, PA, USA) unless otherwise stated.
2.3. Determination of indoleamine 2,3-dioxygenase (IDO EC 1.13.11.52)
activity and kynurenine levels
Brieﬂy, growing HFF monolayers were treated with NPs in the
presence or absence of RH-2F infection. After a 24- or 48-h incubation
at 37 °C, cells were scrapped and washed three times with cold PBS at
2500×g for 10 min (Cold centrifuge; Hitachi, Japan). The cells were re-
suspended in M-PER lysis buﬀer (Thermo-Fisher, Waltham, MA, USA).
The mixture was gently shaken for 10 min and cell debris removed by
centrifugation at 14,000×g for 15 min. The supernatant was trans-
ferred to a new tube for immediate biochemical analysis. For IDO ac-
tivity determination, a Sandwich human ELISA assay kit (Cloud-Clone,
Houston, TX, USA) was used. The assay was performed according to the
manufacturer's instructions.
To determine the concentration of kynurenine in cell supernatant,
we used the protocol described by Braun et al. [20] with slight mod-
iﬁcation. Brieﬂy, 100 μL of 30% trichloroacetic acid (TCA) was added
to 100 μL of culture supernatant and incubated for 30 min at 50 °C to
hydrolyze N-formylkynurenine to kynurenine. This was then vortexed,
and centrifuged at 8500×g for 5 min. An aliquot (100 μL) of the su-
pernatant was then mixed with an equal volume of freshly prepared
Ehrlich reagent (2%; 100 mg P-dimethylbenzaldehyde in 5 ml of glacial
acetic acid) in a micro-titer plate well (96-well format). After a 10-min
incubation at room temperature, the optical density was measured at
492 nm by using a microplate reader (MTP 500; Corona Electric, Hi-
tachinaka, Japan). The level of kynurenine in the culture supernatant
was extrapolated from a calibration curve of deﬁned kynurenine con-
centrations (0–250 μM).
2.4. Chemical induction of hypoxia
Chemical hypoxia was induced in HFF cells by following the pro-
cedure described by Wu and Yotnda (2011). Brieﬂy, growing HFF cells
were treated with CoCl2 (0.1 µM ﬁnal concentration) and incubated for
24 h at 37 °C. Successful hypoxia induction was conﬁrmed by mea-
suring the HIF-1α level and comparing it with that of the untreated
control.
2.4.1. Determination of hypoxia-inducing factor 1-alpha (HIF-1α) levels
HIF-1α was detected by using a cell-based human ELISA Kit (Cell
Biolabs, Inc., San Diego, CA, USA) developed for rapid detection of HIF-
1α in ﬁxed cells. The assay was performed according to the manufac-
turer's instructions. Brieﬂy, growing HFF monolayers in solid white
microplate wells (96-well format) were treated with NPs in the presence
or absence of RH-2F infection. After a 24-h incubation at 37 °C, cells
were ﬁxed, permeabilized, and then neutralized in the well. HIF-1α was
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then detected with an anti-HIF-1α antibody followed by a horseradish
peroxidase-conjugated secondary antibody by luminescence using a
microplate reader (GloMax-Multi Detection System, Promega, Madison,
WI, USA). To validate the detection assay, 3-(5′-Hydroxymethyl-2′-
furyl)-1-benzyl indazole (YC-1) a known inhibitor of HIF-1α activation
[21,22] and the chemical hypoxia inducer CoCl2 [23] were included in
the assay.
2.5. Data analysis
Data were analyzed by using one-way ANOVA (GraphPad Software
Inc., San Diego, CA, USA) and are presented as the mean± standard
error of mean (SEM). Comparisons among groups were determined by
using Tukey's test. P-values< 0.05 were considered to be statistically
signiﬁcant (GraphPad Software Inc., San Diego, CA, USA).
3. Results
3.1. Anti-parasitic action of NPs may be linked to modulation of the host
tryptophan pathway
Previously, we determined that a host cell target might partly
mediate the anti-parasitic action of NPs [6]. Therefore, here we sought
to identify likely host cellular processes involved in mediating the anti-
parasitic action of NPs. We found that addition of L-tryptophan to the
culture medium relieved the NP-induced restriction on parasite growth
(Fig. 1a–c). For all three types of NP (AuNP, AgNP, and PtNP), the EC50
values were signiﬁcantly increased when L-tryptophan was added to
the culture medium. This ﬁnding suggests that the host tryptophan
pathway might contribute to the anti-parasitic action of NPs. This is
consistent with the fact that T. gondii is an auxotroph for tryptophan
and restricting access to this nutrient may limit its growth. To further
conﬁrm the involvement of the host tryptophan pathway in the anti-
parasitic action of NPs, we examined IDO activity in the presence and
absence of T. gondii infection and/or NP treatment. NP treatment in-
creases IDO activity in the presence of T. gondii infection (Fig. 2a,b),
whereas in the untreated control, IDO activity was reduced in the
presence of T. gondii infection compared with when there was no in-
fection. Furthermore, in light of our earlier ﬁnding [6] that the anti-
parasitic action of NPs was linked to the production of reactive oxygen
species (ROS) and that the presence of an antioxidant (trolox) reversed
the anti-parasitic eﬀect of NPs, we added trolox to the culture medium
to assess its eﬀect on IDO activity. We found that trolox attenuated the
eﬀect of NPs on the activity of IDO in the presence of T. gondii infection
(Fig. 2c,d). In the absence of T. gondii infection, trolox addition failed to
suppress the IDO activity particularly in the presence of PtNP.
IDO catalyzes the regulatory step in the degradation of tryptophan.
The increase in IDO activity by NP treatment may indicate that tryp-
tophan was being degraded. Therefore, we determined the level of
kynurenine (the degradation product of tryptophan) in the absence and
presence of T. gondii infection and/or NP treatment. We found that only
AgNP treatment appreciably increased the level of kynurenine in the
absence as well as in the presence of T. gondii infection compared with
the control (Fig. 3a,b). Moreover, for AgNP treatment, the addition of
trolox had no detectable eﬀect on the level of kynurenine in the absence
or presence of T. gondii infection (Fig. 3c,d). While this is consistent
with our earlier ﬁndings [6] that antioxidants reduce the anti-parasitic
action of NPs, the ﬁndings herein may indicate that the interplay be-
tween cellular oxidative stress and modulation of the host tryptophan
pathway might contribute to the NP anti-parasitic action. Furthermore,
our data indicate that the eﬀect of NP treatment on IDO activity and the
level of kynurenine may not be time dependent because there was no
signiﬁcant change in IDO activity or the level of kynurenine between
the 24 and 48 h NP treatments (Figs. 2a, 3a, and 4a, b). When we
checked to see whether a non-competitive (naphthoquinone derivative;
NQ) or a competitive (1-Methyl-D-tryptophan; DMT) inhibitor of IDO
could abate the anti-parasitic action of NPs, we found that both IDO
inhibitors ameliorated the NP-induced restriction of parasite growth
(Fig. 5a–e). Together, the ﬁndings underscore the likely involvement of
the host tryptophan pathway in the anti-parasitic eﬀect of NPs.
Apart from oxidative stress, activation of IFN-γ could also drive
increased IDO activity. Although HFF cells are not known for IFN-γ
secretion, as this is mainly secreted by natural killer cells and macro-
phages, HFF cells do have IFN-γ receptors. Therefore, we examined
whether the NP anti-parasitic eﬀect had any connection to IFN-γ by
adding dexamethasone (1 µM ﬁnal concentration) to the assay medium.
Previous studies [24,25], have shown that dexamethasone (a gluco-
corticoid) can inhibit IFN-γ functions. In the present study, however,
addition of dexamethasone had no eﬀect on the NP-induced restriction
of parasite growth (Fig. 6a–d), thus suggesting that host IFN-γ has no
role in the anti-parasitic action of the NPs.
3.2. NPs modulate HIF-1α levels
T. gondii infection causes host cell hypoxia and activates host HIF-1α
signaling as part of the T. gondii growth and survival strategy [15]. Yet,
modulation of HIF-1α activity aﬀects the tryptophan pathway through
IDO activity [17]. Therefore, we examined whether HIF-1α activity was
involved in mediating the NP anti-parasitic action. First, we added
CoCl2 (0.1 µM ﬁnal concentration) to the culture medium to mimic
chemical hypoxia. Addition of CoCl2 mitigated the anti-parasitic action
of the NPs and raised the EC50 values (Fig. 7a–c). While these ﬁndings
suggest involvement of cellular hypoxia, they are not deﬁnitive.
Therefore, we determined the HIF-1α level in the presence and absence
of T. gondii infection and/or NP treatments. The data showed that NPs
caused a reduction in the level of HIF-1α both in the absence as well as
in the presence of T. gondii infection (Fig. 8a,b). In contrast, the level of
HIF-1α was elevated by T. gondii infection as well as by CoCl2 treat-
ment. YC-1 (2 µM ﬁnal concentration), which was included as positive
control, reduced the HIF-1α level, thus validating the detection assay.
Moreover, YC-1 restricted T. gondii infection but CoCl2 treatment al-
lowed unhindered parasite growth (Fig. 8c). Further, YC-1 increased
IDO activity in the absence as well as in the presence of T. gondii in-
fection (Fig. 9a,b). However, in cells treated with CoCl2, IDO activity
decreased both in the absence as well as in the presence of T. gondii
infection. The level of kynurenine was not linked to the IDO activity as
Fig. 1. Parasite viability. Toxoplasma gondii-infected HFF monolayers were co-treated with nanoparticles and/or L-tryptophan at the indicated concentration and parasite viability was
determined after a 48-h incubation. [A] Treatment with AuNP and/or 100 µM L-tryptophan; [B] Treatment with AgNP and/or 100 µM L-tryptophan; [C] Treatment with PtNP and/or
100 µM L-tryptophan. Data are expressed as the mean± standard error of mean (SEM). The experiment was performed in triplicate and repeated three times independently. ‘hpi’ is hours
post-infection.
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modulated by either YC-1 or CoCl2 treatment (Fig. 9c,d). Taken to-
gether, these ﬁndings suggest that the anti-parasitic action of NPs might
be due in part to the interplay between multiple host processes
(Fig. 10).
4. Discussion
Although studies have shown that ROS generation by NPs, including
AgNP and AuNP, could in part be responsible for the anti-parasitic
action of NPs [26,27], the anti-microbial and/or anti-parasitic mode of
action of these NPs remains largely unknown. We recently showed that
production of intracellular ROS and by the extension of cellular oxi-
dative stress contributes in part to the anti-T. gondii action of NPs [6].
Herein, we provide evidence that suggests the interplay among multiple
host cellular processes partly mediates the anti-parasitic action of NPs.
Firstly, addition of tryptophan attenuated the anti-parasitic action of
NPs, thus indicating the likely involvement of the host tryptophan
pathway in the anti-parasitic action of NPs. NP treatment probably
caused depletion of the local tryptophan concentration in the host cells
thereby starving the T. gondii of this required nutrient. This is consistent
with previous reports of the host tryptophan pathway as a critical anti-
parasitic strategy [11,17,18].
Our data further showed that NP treatment elevated IDO activity in
the presence but not in the absence of T. gondii infection. The reason for
this disparity is not known but may be connected to infection-induced
alterations in host cell physiology, which suggests that NPs may act
diﬀerently depending on whether a physiological stressor or stimulator
like infection is present. However, the fact that IDO activity was ele-
vated by NP treatment in the presence of T. gondii supports the notion
that modulation of the host tryptophan pathway might be involved in
the anti-parasitic action of NPs. Although, in the present study, the level
of kynurenine did not increase concomitantly with the elevated IDO
activity, except for in response to AgNP treatment (which resulted in an
appreciable increase in the level of kynurenine), NP-induced elevation
of IDO activity suggests involvement of the host tryptophan pathway in
the anti-parasitic action of NPs. Moreover, non-competitive and com-
petitive inhibitors of IDO reduced the anti-parasitic eﬀect of NPs, thus
providing additional evidence that host tryptophan pathway is
Fig. 2. Indoleamine 2,3-dioxygenase (IDO) activity. IDO activity was assessed in the absence or presence of Toxoplasma gondii infection and following a 24-h treatment with nanoparticles
and/or trolox. [A] IDO activity determined in the absence of T. gondii infection; [B] IDO activity determined in the presence of T. gondii infection; [C] IDO activity determined in the
absence of T. gondii infection but in the presence of 100 µM trolox; [D] IDO activity determined in the presence of T. gondii plus 100 µM trolox. Data are expressed as the mean± SEM (n
= 3); α is signiﬁcant at p<0.05, β is signiﬁcant at p<0.001, γ is signiﬁcant at p<0.0001 relative to the control. ‘hpi’ is hours post-infection.
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probably involved in mediating the anti-parasitic action of NPs. In
addition, the changes in IDO activity and kynurenine levels as pre-
sented herein suggest that activation of the host kynurenine pathway
was subtle and possibly a minor and/or secondary eﬀect.
Addition of trolox abated the NP-induced elevation in IDO activity,
suggesting that the anti-parasitic action of NPs might be partially due to
interplay among multiple host processes, including but not limited to
oxidative stress and modulation of the host tryptophan pathway. The
fact that NP treatment caused host tryptophan depletion may be con-
nected to its potential to cause ROS production. Recently, we showed
that ROS production and to a larger extent cellular oxidative stress was
in part responsible for the anti-parasitic action of NPs [6]. Therefore, it
is conceivable that NP-induced oxidative stress may promote modula-
tion of the host tryptophan pathway in the way that aﬀects parasite
growth. This line of thought is supported by reports that associate
oxidative stress with activation of the kynurenine pathway [28,29]. In
addition, the ﬁnding that the anti-parasitic action of NPs was not
attenuated in the presence of dexamethasone, a potent inhibitor of IFN-
γ, seems to indicate that the increased IDO activity was not a result of
IFN-γ–driven functions. This concept is supported by the knowledge
that NPs have the capacity to activate IFN-γ expression [30]. We did not
determine IFN-γ levels in the present study because HFF cells may be
deﬁcient for IFN-γ secretion as this cytokine is mainly secreted by
natural killer cells and macrophages. However, it would be logical that
if IFN-γ secretion was involved in the NP anti-parasitic action, then the
addition of dexamethasone would ameliorate the parasite growth re-
striction caused by NPs. However, this was not the case, thus suggesting
that IFN-γ functions do not contribute to the anti-parasitic action of
NPs. Our ﬁnding provides additional evidence that mediation of the NP
anti-parasitic action through increased IDO activity might be linked to
NP-induced oxidative stress. Taken together, our data suggest that
subtle modulation of the host tryptophan pathway contributes at least
in part to the anti-parasitic action of NPs. This may not be unexpected
or surprising if we consider that previous studies [17,18] have pointed
Fig. 3. Level of kynurenine. The level of kynurenine was determined in the absence or presence of Toxoplasma gondii infection and following a 24-h treatment with nanoparticles and/or
trolox. [A] Level of kynurenine determined in the absence of T. gondii infection; [B] Level of kynurenine determined in the presence of T. gondii infection; [C] Level of kynurenine
determined in the absence of T. gondii infection but in the presence of 100 µM trolox; [D] Level of kynurenine determined in the presence of T. gondii plus 100 µM trolox. Data are
expressed as the mean± SEM (n = 3); α is signiﬁcant at p<0.05 and γ is signiﬁcant at p<0.0001 relative to the control. ‘hpi’ is hours post-infection.
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to tryptophan starvation as a viable anti-T. gondii strategy.
HIF-1 is a major regulator of energy homeostasis and cellular
adaptation to low oxygen stress. Increases in HIF-1 protein levels and
activity are not restricted to hypoxic stress since many pathogens in-
cluding T. gondii activate host HIF-1 as part of their growth strategies
[14,17]. The ﬁnding that NP treatment decreased the level of HIF-1α in
the presence and absence of T. gondii infection lends additional support
to our belief that the anti-parasitic action of NPs is linked to multiple
host cellular processes including but not limited to oxidative stress [6]
as well as the modulation of HIF-1α levels and the local pool of host
tryptophan. Perhaps NP treatment causes oxidative stress and reduces
the level of HIF-1α as part of its primary anti-parasitic action. In this
scenario, the elevated IDO activity would be a secondary eﬀect. The NP-
induced increase in IDO activity was mild and subtle without a deﬁnite
concomitant increase in the level of kynurenine except for in response
to AgNP treatment. Meanwhile, studies have shown that cellular oxi-
dative stress [28,29] as well as HIF-1α [17] can modulate IDO activity
and to a greater extent activate the kynurenine pathway. Our conten-
tion that NP-induced oxidative stress and the reduced level of HIF-1α
may together trigger an increase in IDO activity is consistent with
Fig. 4. Indoleamine 2,3-dioxygenase (IDO) activity and level of kynurenine after a 48-h treatment with nanoparticles and/or trolox. IDO activity and level of kynurenine were determined
in the absence of Toxoplasma gondii infection and following a 48-h incubation. [A] IDO activity determined in the absence of T. gondii infection; [B] Level of kynurenine determined in the
absence of T. gondii infection. Data are expressed as the mean±SEM (n = 3); γ is signiﬁcant at p<0.0001 relative to the control. ‘hpi’ is hours post-infection.
Fig. 5. Parasite viability. Toxoplasma gondii-infected HFF monolayers were either singly or co-treated with nanoparticles and (± )3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[(phenylmethyl)
amino]−2H-naphtho[2,3-b]pyran-5,10-dione (a naphthoquinone derivative – NQ) or 1-Methyl-D-tryptophan (DMT) at the indicated concentration and parasite viability was determined
after a 48-h incubation. [A] Treatment with AuNP and/or 0.1 µM NQ; [B] Treatment with AgNP and/or 0.1 µM NQ; [C] Treatment with PtNP and/or 0.1 µM NQ; [D] Single dose
treatment with NPs and/or 0.1 µM NQ; [E] Single dose treatment with NPs and/or 100 µM DMT. Data are expressed as the mean± SEM. The experiment was performed in triplicate and
repeated three times independently. α is signiﬁcant at p<0.05, β at p<0.001 and γ at p<0.0001 versus control. ‘hpi’ is hours post-infection.
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previous reports [15,17,31] that have linked increased IDO activity and
depletion of local tryptophan levels to reduced cellular levels of HIF-1α.
Moreover, in the present study, YC-1 (a potent HIF-1α inhibitor) in-
creased IDO activity in the presence as well as in the absence of T. gondii
infection. Therefore, it is plausible that the NP-induced reduction in
HIF-1α levels contributes to the elevated IDO activity. Additional sup-
port that interplay between host HIF-1α and IDO activity contributes to
the anti-parasitic action comes from the fact that CoCl2 treatment de-
creased IDO activity in the present study. This was likely due to the
ability of CoCl2 to induce chemical hypoxia [23] and thus increase the
expression of HIF-1α, as was the case herein. Interestingly, while YC-1
restricted T. gondii growth, CoCl2 showed no detectable anti-parasitic
eﬀect in the present study (at least at the dose that induced chemical
hypoxia). Together, our ﬁndings implicate modulation of host HIF-1α,
IDO activity, and the tryptophan pathway in the anti-parasitic action of
NPs. To this end, a proposed mechanism and/or connection might be
that NP treatment primarily causes oxidative stress and modulates the
level of HIF-1α, which subsequently leads to an increase in IDO activity
thus pushing the tryptophan pathway towards kynurenine production.
The probable outcome of activating the kynurenine pathway would be a
decrease in the local tryptophan pool, which would starve the parasite
of an essential nutrient and thus restrict its growth.
5. Conclusion
Our data suggest that interplay among multiple host processes, in-
cluding modulation of HIF-1α activity, IDO activity, and the tryptophan
pathway, contributes to the anti-parasitic action of NPs. To our
knowledge, this is the ﬁrst study to demonstrate an eﬀect of NPs on the
tryptophan and/or kynurenine pathway. Further, our ﬁndings suggest
that NP treatment might produce diﬀerent outcomes depending on
whether a physiological stressor or stimulator like infection is present
or not. Taken together, these ﬁndings not only deepen our under-
standing of the mechanism of action of NPs but also demonstrate that
modulation of the host nutrient pool is a viable approach to the de-
velopment of new and eﬀective anti-parasitic agents. Future in-
vestigations should include evaluating the anti-parasitic potential of
NPs in a mouse or other animal model.
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Fig. 6. Parasite viability. Toxoplasma gondii-infected HFF monolayers were either singly or co-treated with nanoparticles and dexamethasone (Dex) at the indicated concentration and
parasite viability was determined after a 48-h incubation. [A] Treatment with AuNP and/or 1 µM Dex; [B] Treatment with AgNP and/or 1 µM Dex; [C] Treatment with PtNP and/or 1 µM
Dex; [D] Single dose treatment with NPs and/or 1 µM Dex. Data are expressed as the mean± SEM. The experiment was performed in triplicate and repeated three times independently. β
is signiﬁcant at p<0.001 and γ at p<0.0001 versus control. ‘hpi’ is hours post-infection.
Fig. 7. Parasite viability. Toxoplasma gondii-infected HFF monolayers were either singly or co-treated with nanoparticles and CoCl2 at the indicated concentration and parasite viability
was determined after a 48-h incubation. [A] Treatment with AuNP and/or 0.1 µM CoCl2; [B] Treatment with AgNP and/or 0.1 µM CoCl2; [C] Treatment with PtNP and/or 0.1 µM CoCl2.
Data are expressed as the mean± SEM. The experiment was performed in triplicate and repeated three times independently. ‘hpi’ is hours post-infection.
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Fig. 8. Level of hypoxia inducing factor – 1 alpha (HIF-1α) and parasite viability. [A] Level of HIF-1α determined in the absence of Toxoplasma gondii infection after a 24-h treatment; [B]
Level of HIF-1α determined in the presence of Toxoplasma gondii infection after a 24-h treatment; [C] Toxoplasma gondii viability determined after a 48-h treatment with 3-(5′-
Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) and CoCl2. Data are expressed as the mean±SEM. The experiment was performed in triplicate and repeated three times in-
dependently. α is signiﬁcant at p<0.05 versus control (no infection), β at p<0.001 versus control (no infection), γ at p<0.0001 versus infection only. ‘hpi’ is hours post-infection.
Fig. 9. Eﬀect of 3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) and CoCl2 on indoleamine 2,3-dioxygenase (IDO) activity after 24 h of treatment with or without trolox. [A] IDO
activity determined in the absence of Toxoplasma gondii infection; [B] IDO activity determined in the presence of Toxoplasma gondii infection; [C] level of kynurenine determined in the
absence of Toxoplasma gondii infection; [D] level of kynurenine determined in the presence of Toxoplasma gondii infection. Data are expressed as the mean± SEM (n = 3). ‘hpi’ is hours
post-infection.
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